A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naïve healthy adults

KD-382 was safe and well-tolerated in flavivirus antibody-naïve healthy subjects. It elicited a long-lasting neutralizing antibody response for all four DENV serotypes during the 1-year follow-up, even with single-dose administration. Australia New Zealand Clinical Trial Registry: ACTRN12618001027202.